TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05588609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Oral Tablet
Description: anti epidermal growth factor receptor (EGFR)/HER2 agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Oral Tablet
Description: anti epidermal growth factor receptor (EGFR)/HER2 agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Pill
Description: second-generation androgen receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Pill
Description: second-generation androgen receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets
Description: androgen synthesis inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets
Description: androgen synthesis inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCLA-128
Description: full length IgG1 bispecific antibody targeting HER2 and HER3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCLA-128
Description: full length IgG1 bispecific antibody targeting HER2 and HER3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCLA-128
Description: full length IgG1 bispecific antibody targeting HER2 and HER3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCLA-128
Description: full length IgG1 bispecific antibody targeting HER2 and HER3
Study: NCT06323356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: Specified drug on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: Specified drug on specified days.
Study: NCT04634552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered SC until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered SC until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered SC until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered SC until disease progression.
Study: NCT05966155

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decisions support
Description: Prescribing recommendations to the provider based on the pharmacogenetic testing results
Study: NCT05189262

Intervention type: OTHER
Intervention: Blood and urine collection
Description: No intervention - Biological specimen collection
Study: NCT06324864

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: START NOW Adapted
Description: The START NOW skills-training combines aspects of cognitive behavioral therapy (CBT), motivational interviewing (MI), dialectical behavior therapy (DBT), Acceptance and Commitment Therapy (ACT) and trauma-sensitive care. Studies in different contexts have shown START NOW's effectiveness in terms of reducing behavioral problems, reducing hospitalization rates, improving mental health functioning and increasing satisfaction rates. The culturally adapted version will be contextually adapted to different cultural backgrounds and the experience of migration. In ten sessions, participants learn about emotions and are introduced to the START NOW skills. These skills, called SLOW DOWN, TAKE A STEP BACK, ACCEPT, RESPECT and TAKE ACTION, are strategies or techniques that can be used to better manage stress and difficult emotions.
Study: NCT05963074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered orally.
Study: NCT06492005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitior
Description: Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitior
Description: Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol
Study: NCT05347095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously/IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously/IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously/IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously/IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously/IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously/IV infusion.
Study: NCT05642182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFA002
Description: Study drug formula without excipient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFA002
Description: Study Drug SFA002 with excipient (Propionate)
Study: NCT05563038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scrambler Therapy
Description: Scrambler Therapy is a non-invasive neuromodulator treatment that focuses on relieving chronic pain through the sending of non-pain signals to the brain through the afferent pain sensory nerves. The signals given off by the scrambler therapy machine are intended to mimic neuronal action potentials through the synthesis of 16 unique waveforms that in combination forms a patient specific cutaneous electrostimulation to reduce pain. These information packets are then carried by the afferent C-fibers, an established system that modulates the sensations received instead of blocking them. The modulated signals are received as nonpainful and endogenous by the central nervous system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medication Management
Description: Medications such as: gabapentin, duloxetine and Lyrica are all FDA approved for treatment of neuropathic pain, particularly that caused by diabetes.
Study: NCT04368949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepping-Up
Description: The intervention group will receive STEPPING-UP, a virtual 12-week, multicomponent intervention that includes tailored task-oriented motor learning exercise and a mobility self-management (SM) program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Coaching Walking Program
Description: The participants assigned to this group will receive a 12-week Telephone-Based Coaching Walking Program (TELE) delivered by a PT who will help participants set short and long term walking goals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chair-Based Yoga Program
Description: Participants assigned to this group will receive a virtual 12-week Chair-Based Yoga Program (YOGA), a group-based exercise control where participants will undertake a seated exercise program that includes: warm up, seated and standing yoga poses, cool down.
Study: NCT04754139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WeChat mobile mini-application
Description: Sexual health education and the role of PrEP
Study: NCT05022849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75229414
Description: JNJ-75229414 infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75229414
Description: JNJ-75229414 infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bridging Therapy
Description: Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bridging Therapy
Description: Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.
Study: NCT05178992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socially Assistive Robot Activity
Description: Participants will attend two weekly sessions with robot activities. Each session will last 30 minutes. Participants will attend robot sessions for 8 weeks.
Study: NCT02586831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 2 mg administered subcutaneously weekly for up to 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 50 mg administered subcutaneously once a month for 1 year.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ATG Placebo
Description: ATG placebo mimicking Thymoglobulin administered intravenously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IL-2 Placebo
Description: IL-2 placebo mimicking Aldesleukin administered subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab Placebo
Description: Placebo mimicking Adalimumab administered subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide Placebo
Description: Placebo mimicking Exenatide administered subcutaneously.
Study: NCT04759508

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flax Oil Capsule
Description: Flaxseed with brand name Flax Oil Capsule will be administered to subjects receiving antihypertensives.
Study: NCT05178992

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Socially Assistive Robot Activity
Description: Participants will attend two weekly sessions with robot activities. Each session will last 30 minutes. Participants will attend robot sessions for 8 weeks.
Study: NCT04759508

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Soya Oil Capsule
Description: Placebo capsule filled with soya oil and inert(inactive) substances will be administered to subjects remaining anti hypertensives.
Study: NCT05670054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
Description: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
Description: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
Study: NCT04122105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
Study: NCT06094842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Receptor-engineered T-cells
Description: Given autologous L1CAM-specific CAR+EGFRt+ T cells IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest x-ray
Study: NCT05936879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Group A: Intervention group will be treated with Inspiratory muscle training and early ambulation and routine physical therapy including ankle pumps,hand pumps isometrics of upper and lower limbs after surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs.
Description: Group B: Control group routine physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs
Study: NCT06436378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention in person
Description: The music intervention consists of listening to two or three pieces of music chosen by each participant that bring them a sense of well-being. One of the two music intervention sessions will be preceded by a moment of relaxation, during which participants will be asked to focus their attention on their breathing, on relaxation, and on the process of self-absorption. This intervention, preceded by a brief moment of relaxation, will take place during the first session for half of the participants and during the second session for the other half.
Study: NCT05705271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (Kerendia, BAY94-8862)
Description: Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
Study: NCT06312683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 MG Oral Tablet [XIFAXAN]
Description: Rifaximin 550 MG Oral Tablet \[XIFAXAN\] Taken twice a day for up to 365 days
Study: NCT05422638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RBSTE
Description: 8-week health promotion group focused on supporting coping with racism and empowerment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PCT
Description: 8-week health promotion group focused on providing support and facilitating problem solving
Study: NCT04591093

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated
Description: Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated
Description: Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated
Study: NCT06500481

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and CSF sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and CSF sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved-Field Radiation Therapy
Description: Undergo IFRT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture
Description: Undergo LP
Study: NCT05571124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise Intervention
Description: Participants will perform stretching and mobility exercises in short bouts of time.
Study: NCT05789888

Intervention type: GENETIC
Intervention: MT-ATP6 mtDNA gene variability in obesity and normal body weight patients.
Description: As part of the research, the MT-ATP6 gene was tested in order to influence the modulation of the amount of fat contained.

Intervention type: GENETIC
Intervention: MT-ATP6 mtDNA gene variability in obesity and normal body weight patients.
Description: As part of the research, the MT-ATP6 gene was tested in order to influence the modulation of the amount of fat contained.

Intervention type: GENETIC
Intervention: SCD gene variability in obesity and normal body weight patients.
Description: As part of the research, the SCD gene was tested in order to influence the modulation of the amount of fat contained.

Intervention type: GENETIC
Intervention: SCD gene variability in obesity and normal body weight patients.
Description: As part of the research, the SCD gene was tested in order to influence the modulation of the amount of fat contained.

Intervention type: OTHER
Intervention: Finding TOFI and FOTI phenotypes in participants with obesity and normal weight.
Description: As part of the research, we measured the amount of VAT and SAT and calculate VAT/SAT ratio as a marker to determine the phenotype of fat tissue.

Intervention type: OTHER
Intervention: Finding TOFI and FOTI phenotypes in participants with obesity and normal weight.
Description: As part of the research, we measured the amount of VAT and SAT and calculate VAT/SAT ratio as a marker to determine the phenotype of fat tissue.
Study: NCT06500481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo LP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Craniospinal Irradiation
Description: Undergo pCSI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06392477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody
Study: NCT04628494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Following mandatory pre-medication subject will be administered epcoritamab as a subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice Chemotherapy
Description: Following mandatory pre-medication subject will be administered intravenously either BR or R-GemOx.
Study: NCT05445232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Administered orally.
Study: NCT06507722

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Timing of OGTT
Description: In Aim 1, timing of oral glucose tolerance test will be altered.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Timing of OGTT
Description: In Aim 1, timing of oral glucose tolerance test will be altered.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Timing of Standardized Meal
Description: In Aim 2, timing of a standardized meal will be altered.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Timing of Standardized Meal
Description: In Aim 2, timing of a standardized meal will be altered.
Study: NCT04727944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reach and grasp tasks in healthy participants using MEG technique (Experiment 1)
Description: Human participants will perform reach and grasp movements to various objects (e.g. a cube, sphere, or rod) driven either by perceived action affordances, or instruction cues. A rotating carousel will be used to present subjects with various objects affording different types of grasps (e.g. a precision pinch, a whole hand 'power' grasp, or a tripod grasp).~Prior to the experiment, subjects will be tested outside the scanner by asking them to grasp each object as they would naturally to ensure that each object elicits the expected grasp type. Subject-specific, 3D-printed head-casts will be created based on high resolution MRI scans from each subject, and worn by subjects during the MEG experiment (Experiment 1) to reduce within-session head movement associated with reaching and grasping.~At the end of this session an experimental task is added: detection of tons in presence of multitonal masks, in order to verify how beta peaks might be generated by a stimulus auditory.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reach and grasp tasks in healthy participants using EEG technique (Experiment 2)
Description: Experiment 2 consists of a task of reaching for and grasping several objects (e.g. a cube, sphere, or rod) ; the task used for experiment 2 is the same as that used for experiment 1. EEG signals will be measured.